Biotest Aktiengesellschaft (HAM:BIO)
| Market Cap | 1.33B |
| Revenue (ttm) | 635.20M |
| Net Income (ttm) | -24.50M |
| Shares Out | n/a |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | 22.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 142 |
| Open | 38.00 |
| Previous Close | 38.00 |
| Day's Range | 38.00 - 38.00 |
| 52-Week Range | 35.00 - 45.60 |
| Beta | n/a |
| RSI | 47.87 |
| Earnings Date | Nov 10, 2025 |
About HAM:BIO
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company’s products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immun... [Read more]
Financial Performance
In 2024, HAM:BIO's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.
Financial StatementsNews
EQS-News: Biotest’s Yimmugo launches in the United States
EQS-News: Biotest AG / Key word(s): Product Launch Biotest’s Yimmugo launches in the United States 09.10.2025 / 17:30 CET/CEST The issuer is solely responsible for the content of this announcement. PR...
EQS-News: Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A.
EQS-News: Biotest AG / Key word(s): AGM/EGM Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A. 19.09.2025 / 15:00 CET/CEST The issuer is solely responsible for the conte...
EQS-News: Biotest AG receives a request from Grifols S.A. to convene an extraordinary general meeting
EQS-News: Biotest AG / Key word(s): Legal Matter Biotest AG receives a request from Grifols S.A. to convene an extraordinary general meeting 04.08.2025 / 13:00 CET/CEST The issuer is solely responsibl...
EQS-News: Biotest AG: Annual General Meeting approves dividend distribution
EQS-News: Biotest AG / Key word(s): AGM/EGM Biotest AG: Annual General Meeting approves dividend distribution 02.07.2025 / 18:08 CET/CEST The issuer is solely responsible for the content of this annou...
EQS-News: Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
EQS-News: Biotest AG / Key word(s): Conference Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine 23.06.2025 / 17:03 CET/CEST The issuer is solely respon...